Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia is expanding its presence in the United States to increase investor awareness and engagement as part of its global growth strategy. The Company’s ongoing Phase 1b/2a clinical trial of narmafotinib (FAK inhibitor) in pancreatic cancer includes sites in both Australia and the U.S., reflecting Amplia’s deepening international footprint.

To complement its clinical progress, Amplia has launched a U.S. capital markets campaign aimed at broadening exposure among U.S. investors. This includes working with financial institutions and initiating an uplisting from the Pink Sheets to the OTCQB Market, designed to enhance access and liquidity for U.S.-based investors.

“As we continue to conduct our Phase 1b/2a clinical trial of narmafotinib, including in the United States, we believe it is important that we reach investors there to help support the program and development of the compound. We believe narmafotinib represents a unique opportunity in the FAK inhibitor class, potentially providing improved balance between efficacy, safety and tolerability beyond what is currently available in the U.S. market and within the class as a whole. The OTCQB market is a unique opportunity to introduce ourselves to the U.S. market and significantly expand our U.S. investor base. We look forward to launching our capital markets campaign and to telling the Amplia story there.”

Amplia to signficantly expand U.S. presence through expansion of clinical and investor facing activities